AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.
- 3D Screen Printing: Enabling A New Generation Of Complex Formulations
- Testing Federal Healthcare Laws: Risks In Genetic-Testing Programs
- Pharma's Guide To Making Health Communications Land Well
- AI In A Time Of Uncertainty: Key Strategies To Enable Flexibility
- A CEO With A General Counsel's Perspective
- Interchangeability In Leadership: A Career Built On Versatility
- An Updated View of The Federal Segment: DHA Formulary Management
- FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance
COMPANIES TO WATCH
-
![Tim Lu_Senti Bio]( "Companies To Watch: Senti Bio")
Companies To Watch: Senti BioSenti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
WHERE ARE THEY NOW
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus PharmaceuticalsTarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 03.26.25 -- A Genetic Medicine Approach To ALS
- 03.25.25 -- Overcoming Payment Challenges
- 03.24.25 -- Testing Federal Healthcare Laws: Risks In Genetic-Testing Programs
- 03.21.25 -- Pharma's Guide To Making Health Communications Land Well
- 03.20.25 -- Discover How To Optimize Productivity In Your mAb Capture
SPOTLIGHT
Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.
